AtonRa Partners Decreases Stock Holdings in Evolent Health, Inc. (NYSE:EVH)

AtonRa Partners decreased its position in Evolent Health, Inc. (NYSE:EVH) by 8.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,301 shares of the technology company’s stock after selling 1,404 shares during the quarter. AtonRa Partners’ holdings in Evolent Health were worth $505,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. HB Wealth Management LLC bought a new stake in shares of Evolent Health during the 4th quarter valued at about $1,425,000. Swiss National Bank boosted its stake in shares of Evolent Health by 8.1% during the 3rd quarter. Swiss National Bank now owns 235,300 shares of the technology company’s stock valued at $6,407,000 after purchasing an additional 17,700 shares in the last quarter. Wellington Management Group LLP boosted its stake in Evolent Health by 11.9% during the third quarter. Wellington Management Group LLP now owns 4,239,198 shares of the technology company’s stock worth $115,433,000 after acquiring an additional 449,664 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Evolent Health by 7.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 847,768 shares of the technology company’s stock worth $23,085,000 after acquiring an additional 59,376 shares in the last quarter. Finally, Cetera Trust Company N.A bought a new stake in Evolent Health during the fourth quarter worth about $303,000.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on EVH shares. Oppenheimer started coverage on shares of Evolent Health in a research note on Friday, March 1st. They set an “outperform” rating and a $45.00 price objective on the stock. Canaccord Genuity Group decreased their target price on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, March 28th. William Blair reissued an “outperform” rating on shares of Evolent Health in a research report on Tuesday, January 9th. Citigroup began coverage on Evolent Health in a research report on Monday, April 22nd. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. reduced their target price on Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Evolent Health presently has an average rating of “Moderate Buy” and an average price target of $42.70.

Evolent Health Trading Up 0.6 %

Shares of Evolent Health stock traded up $0.17 on Monday, reaching $27.82. The company had a trading volume of 640,331 shares, compared to its average volume of 943,359. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of -21.91 and a beta of 1.54. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The firm’s 50-day moving average price is $31.71 and its two-hundred day moving average price is $30.29. Evolent Health, Inc. has a 1 year low of $23.33 and a 1 year high of $36.70.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The company had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. As a group, research analysts predict that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.